The Urgent Need for Better Therapies: Tackling the Challenges of Pompe Disease

Did you know? Pompe disease is a severe genetic disorder. Even if treated, those with infant-onset Pompe rarely survive beyond early childhood. The current standard treatment, enzyme replacement therapy (ERT), can extend life expectancy into adolescence. However, ERT has significant shortcomings. It does not target skeletal muscle effectively, leading to progressive muscle weakness and respiratory issues over time. Moreover, ERT requires lifelong bi-weekly infusions, which can be burdensome for patients and families.

There is an urgent unmet need for more efficient therapies that can provide better disease management, improve quality of life, and extend survival.

At Sutura Therapeutics, we're committed to addressing this unmet need by developing targeted treatments that significantly improve outcomes for patients with this severe disease.

Follow us to learn more about our efforts and the latest developments in Pompe disease research.

#PompeDisease #RareDiseases #HealthcareInnovation #FightRareDiseases